PureTech’s Gallop Oncology to Present Promising Phase 1b Data of LYT-200 in Relapsed/Refractory AML at the 2025 ASH Annual Meeting PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a biotherapeutics innovator renowned for its hub-and-spoke model that…
Auna S.A. Reports Early Results of Cash Tender Offer and Consent Solicitation for 10.000% Senior Secured Notes Due 2029 Auna S.A. (NYSE: AUNA), a Luxembourg-based public limited liability company and one of Latin America’s leading integrated healthcare providers, announced the…
Agenus Reports Durable Two-Year Survival with BOT/BAL Combination Across Refractory Solid Tumors at ESMO 2025 Agenus Inc. (Nasdaq: AGEN), a biotechnology company recognized for its pioneering work in immuno-oncology, unveiled highly encouraging new clinical data from its novel combination therapy…
Sanofi and EVOQ Therapeutics Form $500 Million Partnership to Advance Autoimmune Therapies Sanofi, a global pharmaceutical giant, has entered into a strategic collaboration with EVOQ Therapeutics, a clinical-stage biotechnology company, to jointly develop and commercialize novel therapies targeting autoimmune diseases.…
FDA’s Orphan Drug Leadership Shifts Amid Policy Changes and Department-Wide Shakeups Sandra Retzky, formerly the top orphan drug regulator at the FDA, is no longer serving as director of the Office of Orphan Products Development. The departure, first reported by…
Roche Showcases Breakthrough Sequencing by Expansion (SBX) Technology and Sets New GUINNESS WORLD RECORD™ at ASHG 2025 Roche (SIX: RO, ROG; OTCQX: RHHBY) unveiled a series of groundbreaking advancements in its Sequencing by Expansion (SBX) technology during the American Society…
Adagio Medical Announces Up to $50 Million Private Placement to Advance Cardiac Arrhythmia Therapies Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or the “Company”), a leading innovator in the development of catheter ablation technologies for the treatment of cardiac arrhythmias,…
Transforming Autoimmune and Inflammatory Disease Therapies WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), proudly congratulates Dr. Fred Ramsdell, PhD, co-founder and Chair of the Scientific Advisory Board of its client Sonoma Biotherapeutics, on being…
Zoetis Receives Health Canada Approval for Lenivia® to Relieve Osteoarthritis Pain in Dogs Zoetis Inc. today announced that Health Canada has approved Lenivia® (izenivetmab injection) for the treatment of pain associated with osteoarthritis (OA) in dogs. Lenivia, a novel monoclonal…
WHO Warns of Global Neurological Health Crisis: Over 11 Million Deaths Annually Demand Urgent Action The World Health Organization (WHO) has issued a stark warning about the growing global burden of neurological disorders, revealing that less than one in three…
WHO and European Union Join Forces to Advance Digital Health Systems Across Sub-Saharan Africa The World Health Organization (WHO) and the European Union (EU) have formally announced a new collaboration aimed at accelerating the digital transformation of health systems in…
LEQEMBI® IQLIK™ Named One of TIME’s Best Inventions of 2025 for Transforming Alzheimer’s Treatment Access Eisai Co., Ltd. and Biogen Inc. today announced that LEQEMBI® IQLIK™ (lecanemab-irmb), the first subcutaneous autoinjector formulation of the Alzheimer’s disease therapy lecanemab, has been…